GT Biopharma reports Q3 EPS ($1.53) vs. ($1.77) last year

The Company had cash and cash equivalents of approximately $6.5M as of September 30, anticipated to be sufficient to fund operations into Q2 2025..”We are pleased to be progressing towards dosing the first patient in our Phase 1 trial evaluating GTB-3650 in cancer patients in the fourth quarter of this year. This dose escalation study will evaluate GTB-3650 in 12 patient with relapsed or refractory CD33 expressing hematologic malignancies, including refractory acute myeloid leukemia AML and high-risk myelodysplastic syndrome . We believe that NK cell engagers, like GTB-3650, have the potential to offer patients with a safer alternative to current treatments, like CAR-T therapy”, said Michael Breen, Executive Chairman and interim Chief Executive Office of GT Biopharma (GTBP).